Firm will evaluate utility of EBx cells in production of MVA-based vaccine.

Vivalis granted Bavarian Nordic rights to evaluate the embryonic stem cell derived EBx® cells as a production platform of MVA-BN®-based (modified vaccinia Ankara-strain) vaccines.


“We firmly believe that Vivalis’ chicken and duck EBx cell lines could be an attractive alternative to chicken embryonic fibroblasts for the industrial production of MVA-based vaccines,” says Franck Grimaud, CEO of Vivalis.